Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
37 Results for "
MEIS
" in MedChemExpress (MCE) Product Catalog:
Products (37)
37 Results for "MEIS" in MCE Product Catalog:
10
10 Publications Verification
Target:
Forschungsgebiete:
EPZ004777 is an effective and selective DOT1L inhibitor, with IC50 being 0.4 nM. EPZ004777 reduces the levels of H3K79me2 and H3K79me1, significantly down-regulating the expression of HOXA9 and MEIS1. EPZ004777 selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis) of leukemia cells. EPZ004777 can be used for the study of leukemia .
10
10 Publications Verification
Target:
Forschungsgebiete:
EPZ004777 hydrochloride is an effective and selective DOT1L inhibitor, with IC50 being 0.4 nM. EPZ004777 hydrochloride reduces the levels of H3K79me2 and H3K79me1, significantly down-regulating the expression of HOXA9 and MEIS1. EPZ004777 hydrochloride selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis) of leukemia cells. EPZ004777 hydrochloride can be used for the study of leukemia .
4
4 Cited Publications
Target:
Forschungsgebiete:
Menin-MLL inhibitor MI-2 is a competitive and selective Menin-MLL interaction inhibitor with an IC50 value of 446 nM and a Ki value of 158 nM. Menin-MLL inhibitor MI-2 downregulates the expression of target genes such as HOXA9 and MEIS1, inhibits proliferation of leukemia cells and induces apoptosis and differentiation. Menin-MLL inhibitor MI-2 is proming for rasearch of MLL-rearranged acute leukemias (e.g., AML, ALL) .
Synonyms: DSP-5336
Target:
Forschungsgebiete:
Enzomenib (DSP-5336) is an orally active Menin inhibitor (IC50=1.4 nM, Kd=6.0 nM). Enzomenib disrupts the interaction between Menin and KMT2A/MLL fusion proteins, specifically inhibits the expression of leukemia driver genes such as HOX/MEIS1, and upregulates ITGAM. Enzomenib effectively induces cell differentiation, inhibits tumor cell proliferation, and suppresses primitive cell colony formation. Enzomenib reduces disease burden and prolongs survival, but causes adverse reactions including differentiation syndrome and QTc interval prolongation. Enzomenib is used for research on relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, and other hematologic malignancies with mixed lineage leukemia (MLL) rearrangements or NPM1 mutations .
Art. -Nr.: HY-172416
CAS. Nr.: 2939850-17-4
Synonyms: ZE63-0302
Target:
Forschungsgebiete:
Balomenib (ZE63-0302) is an orally bioavailable menin-KMT2A interaction inhibitor. Balomenib disrupts menin-KMT2A binding, reverses aberrant HOX gene expression. Balomenib inhibits Meis1 mRNA expression in KMT2A-rearranged acute myeloid leukemia cells. Balomenib can be used for the research of leukemia .
Target:
Forschungsgebiete:
MEISi-1 is a small-molecule inhibitor targeting the homeodomain of the MEIS1 protein. MEISi-1 significantly inhibits the activity of luciferase reporter genes containing MEIS binding sites (TGACAG), and induces the self-renewal of a key type of mouse and human hematopoietic stem cells (HSC) both in vitro and in vivo. MEISi-1 promotes cardiomyocyte proliferation and cytokinesis, reduces cardiac fibroblast proliferation, and upregulates the expression of cardiomyocyte-specific genes. MEISi-1 can be used in research on hematological diseases, cardiac regeneration and cancer .
MEISi-2 is a selective inhibitor of MEIS, a key regulator of hematopoietic stem cell (HSC) self-renewal. MEISi-2 is developed for the research of cardiac injuries, hematopoiesis issues, bone marrow transplantations, and cancer .
Art. -Nr.: HY-RS08325
Target:
Forschungsgebiete:
MEIS1 Human Pre-designed siRNA Set A contains three designed siRNAs for MEIS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Art. -Nr.: HY-155797
CAS. Nr.: 2654081-27-1
Synonyms: (S)-JNJ-75276617; (S)-Menin-MLL inhibitor 24
Target:
Forschungsgebiete:
(S)-Bleximenib (Compound 28) ((S)-JNJ-75276617) is an isoform of Bleximenib (HY-148669). (S)-Bleximenib shows an IC50 greater than 1 μM in the MEIS1 mRNA expression assay. (S)-Bleximenib can be used in the research of acute myeloid leukemia .
Art. -Nr.: HY-160018
CAS. Nr.: 2163769-52-4
Target:
Forschungsgebiete:
BAY-155 is a potent and selective menin-MLL tool inhibitor, with an IC50 of 8 nM. BAY-155 leads to a strong expression down-regulation of the MEIS1 gene and up-regulation of CD11b and MNDA genes. BAY-155 shows anti-proliferative effects in AML/ALL (acute myeloid/lymphoblastic leukemia) models .
Art. -Nr.: HY-178172
Forschungsgebiete:
AF9/ENL-DOT1L/AF4 PPI-IN-1 is a potent AF9/ENL and histone methyltransferase DOT1L/AF4 protein-protein interactions (PPI) inhibitor. AF9/ENL-DOT1L/AF4 PPI-IN-1 can inhibit the AF9-DOT1L (IC50 = 1.5 μM), AF9-AF4 (IC50 = 1 μM), ENL-AF4 (IC50 = 1.2 μM) interactions. AF9/ENL-DOT1L/AF4 PPI-IN-1 can suppress the expression of Mixed lineage leukemia (MLL) target genes Myc and Meis1 and selectively block the proliferation of MLL-r and several other leukemia cells. AF9/ENL-DOT1L/AF4 PPI-IN-1 exhibits significant antitumor activities in a mouse model of MLL-r leukemia without overt toxicities. AF9/ENL-DOT1L/AF4 PPI-IN-1 can be used for the study of MLL-r leukemia .
Art. -Nr.: HY-RS08326
Target:
Forschungsgebiete:
MEIS2 Human Pre-designed siRNA Set A contains three designed siRNAs for MEIS2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Art. -Nr.: HY-RS08327
Target:
Forschungsgebiete:
MEIS3 Human Pre-designed siRNA Set A contains three designed siRNAs for MEIS3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Art. -Nr.: HY-RS22635
Target:
Forschungsgebiete:
Meis2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Meis2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Art. -Nr.: HY-RS25706
Target:
Forschungsgebiete:
Meis1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Meis1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Art. -Nr.: HY-RS08319
Target:
Forschungsgebiete:
MEI1 Human Pre-designed siRNA Set A contains three designed siRNAs for MEI1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Art. -Nr.: HY-RS27893
Target:
Forschungsgebiete:
Mei1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mei1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
